NLRP3-IN-38
NLRP3-IN-38 (Compound 18) is an inhibitor for NOD-like receptor protein 3 (NLRP3), that inhibits NLRP3 inflammasome activation with an EC50 of 23 nM.
For research use only. We do not sell to patients.
- CAS No.: 3033054-46-2
- Formula: C21H21F3N4O2
- Molecular Weight:418.41
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
|
NLRP3 inflammasome 23 nM (EC50) |
Chemical Information
-
CAS No. 3033054-46-2
-
Molecular Weight 418.41
-
Formula C21H21F3N4O2
-
SMILES
C[C@H]1CN(C[C@H]([C@@H]1O)C)C2=C3C=NC=CC3=C(N=N2)C4=CC=C(C=C4O)C(F)(F)F
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)